NCT04027361View on ClinicalTrials.gov

Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

October 15, 2021

Study Completion Date

October 15, 2021

Conditions
ADHD
Interventions
DRUG

Amphetamine Extended Release (ER) Tablet 20 mg

A single 20 mg dose of amphetamine ER Tablet, orally administered

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Massachusetts Institute of Technology

OTHER

lead

Tris Pharma, Inc.

INDUSTRY

NCT04027361 - Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD) | Biotech Hunter | Biotech Hunter